• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dipeptidyl peptidase-4 inhibitors increase the risk of bullous pemphigoid in older patients with diabetes: A retrospective analysis using the Korean National Health Insurance Database.

作者信息

Kang H, Lee E B, Lee S, Go T-H, Lee J Y, Lee S-H, Song S A, Lim H K, Hong S-P

机构信息

Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea.

Department of Anesthesiology and Pain Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.

出版信息

J Eur Acad Dermatol Venereol. 2023 Jul;37(7):e879-e881. doi: 10.1111/jdv.18975. Epub 2023 Feb 27.

DOI:10.1111/jdv.18975
PMID:36799763
Abstract
摘要

相似文献

1
Dipeptidyl peptidase-4 inhibitors increase the risk of bullous pemphigoid in older patients with diabetes: A retrospective analysis using the Korean National Health Insurance Database.
J Eur Acad Dermatol Venereol. 2023 Jul;37(7):e879-e881. doi: 10.1111/jdv.18975. Epub 2023 Feb 27.
2
Commentary on 'Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors'.关于“大疱性类天疱疮中糖尿病患病率的变化：是二肽基肽酶 -4 抑制剂所致”的评论
J Eur Acad Dermatol Venereol. 2018 Dec;32(12):e439-e440. doi: 10.1111/jdv.14965. Epub 2018 May 3.
3
Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid.合并用药与二肽基肽酶-4抑制剂相关的大疱性类天疱疮。
An Bras Dermatol. 2021 Nov-Dec;96(6):782-784. doi: 10.1016/j.abd.2020.10.010. Epub 2021 Sep 30.
4
[Association between bullous pemphigoid and dipeptidyl peptidase-4 inhibitors and impact of their withdrawal].大疱性类天疱疮与二肽基肽酶-4抑制剂之间的关联及其撤药的影响
Aten Primaria. 2023 Apr;55(4):102586. doi: 10.1016/j.aprim.2023.102586. Epub 2023 Feb 24.
5
Comment on "Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study".关于“除二肽基肽酶-4抑制剂外的口服降糖药与大疱性类天疱疮无关：一项芬兰全国性病例对照研究”的评论
J Am Acad Dermatol. 2018 Dec;79(6):e111-e112. doi: 10.1016/j.jaad.2018.06.043.
6
Reply to: "Comment on 'Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study'".回复：“对‘除二肽基肽酶-4抑制剂外的口服降糖药与大疱性类天疱疮无关：一项芬兰全国性病例对照研究’的评论”
J Am Acad Dermatol. 2018 Dec;79(6):e113-e114. doi: 10.1016/j.jaad.2018.06.042.
7
Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor.与使用二肽基肽酶-4抑制剂相关的大疱性类天疱疮。
CMAJ. 2022 May 24;194(20):E705. doi: 10.1503/cmaj.211933.
8
Neutrophil to lymphocyte ratio is predictive of severe complications and mortality in patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: A retrospective longitudinal observational study.中性粒细胞与淋巴细胞比值可预测二肽基肽酶-4抑制剂相关大疱性类天疱疮患者的严重并发症和死亡率：一项回顾性纵向观察研究。
J Am Acad Dermatol. 2022 Jun;86(6):1387-1390. doi: 10.1016/j.jaad.2021.05.043. Epub 2021 May 29.
9
Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.二肽基肽酶-4 抑制剂致大疱性类天疱疮的风险异质性：一项基于日本后期高龄者医疗数据库的人群队列研究。
J Diabetes Investig. 2023 Jun;14(6):756-766. doi: 10.1111/jdi.14004. Epub 2023 Mar 10.
10
Dipeptidyl Peptidase-4 Inhibitor Induced Bullous Pemphigoid Complicated by Acquired Reactive Perforating Dermatosis.二肽基肽酶-4抑制剂诱发大疱性类天疱疮并伴有获得性反应性穿通性皮病
Actas Dermosifiliogr. 2022 Oct;113(9):914-915. doi: 10.1016/j.ad.2021.01.023. Epub 2022 May 27.

引用本文的文献

1
GLP-1 Receptor Agonists, DPP-4 Inhibitors and the Skin-Diabetes Meets Dermatology: A Brief Narrative Review.胰高血糖素样肽-1受体激动剂、二肽基肽酶-4抑制剂与皮肤——糖尿病与皮肤病学的交汇：一篇简要叙述性综述
Adv Ther. 2025 Jun 5. doi: 10.1007/s12325-025-03257-w.
2
Dermatological side effects of dipeptidyl Peptidase-4 inhibitors in diabetes management: a comprehensive review.二肽基肽酶-4抑制剂在糖尿病管理中的皮肤副作用：一项综述
Clin Diabetes Endocrinol. 2024 Mar 25;10(1):6. doi: 10.1186/s40842-024-00165-w.